{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:54:43Z","timestamp":1789646083886,"version":"4.0.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T00:00:00Z","timestamp":1691366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T00:00:00Z","timestamp":1691366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["R01AR076516"],"award-info":[{"award-number":["R01AR076516"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["R01AR076516"],"award-info":[{"award-number":["R01AR076516"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["R01AR076516"],"award-info":[{"award-number":["R01AR076516"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["R01AR073764"],"award-info":[{"award-number":["R01AR073764"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["R01AR076516"],"award-info":[{"award-number":["R01AR076516"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["R01AR076516"],"award-info":[{"award-number":["R01AR076516"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["R01AR076516"],"award-info":[{"award-number":["R01AR076516"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012051","name":"Lupus Research Alliance","doi-asserted-by":"publisher","award":["BMS Accelerator Award"],"award-info":[{"award-number":["BMS Accelerator Award"]}],"id":[{"id":"10.13039\/100012051","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Antinuclear antibodies (ANA) are antibodies present in several autoimmune disorders. However, a large proportion of the general population (20%) also have a positive test; very few of these individuals will develop an autoimmune disease, and the clinical impact of a positive ANA in them is not known. Thus, we test the hypothesis that ANA\u2009+\u2009test reflects a state of immune dysregulation that alters risk for some clinical disorders in individuals without an autoimmune disease.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We performed high throughput association analyses in a case\u2013control study using real world data from the de-identified electronic health record (EHR) system from Vanderbilt University Medical Center.<\/jats:p>\n                <jats:p>The study population included individuals with an ANA titer\u2009\u2265\u20091:80 at any time (ANA\u2009+) and those with negative results (ANA-). The cohort was stratified into sub-cohorts of individuals with and without an autoimmune disease. A phenome-wide association study (PheWAS) adjusted by sex, year of birth, race, and length of follow-up was performed in the study cohort and in the sub-cohorts. As secondary analyses, only clinical diagnoses after ANA testing were included in the analyses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The cohort included 70,043 individuals: 49,546 without and 20,497 with an autoimmune disease, 26,579 were ANA\u2009+\u2009and 43,464 ANA-. In the study cohort and the sub-cohort with autoimmune disease, ANA\u2009+\u2009was associated (<jats:italic>P<\/jats:italic>\u2009\u2264\u20095\u2009\u00d7\u200910<jats:sup>\u20135<\/jats:sup>) with 88 and 136 clinical diagnoses respectively, including lupus (OR\u2009\u2265\u20095.4, <jats:italic>P<\/jats:italic>\u2009\u2264\u20097.8\u2009\u00d7\u200910<jats:sup>\u2013202<\/jats:sup>) and other autoimmune diseases and complications. In the sub-cohort without autoimmune diseases, ANA\u2009+\u2009was associated with increased risk of Raynaud\u2019s syndrome (OR\u2009\u2265\u20092.1) and alveolar\/perialveolar-related pneumopathies (OR\u2009\u2265\u20091.4) and decreased risk of hepatitis C, tobacco use disorders, mood disorders, convulsions, fever of unknown origin, and substance abuse disorders (OR\u2009\u2264\u20090.8). Analyses including only diagnoses after ANA testing yielded similar results.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>A positive ANA test, in addition to known associations with autoimmune diseases, Raynaud\u2019s phenomenon, and idiopathic fibrosing alveolitis related disorders, is associated with decreased prevalence of several non-autoimmune diseases.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s41927-023-00349-4","type":"journal-article","created":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T08:03:04Z","timestamp":1691395384000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Clinical diagnoses associated with a positive antinuclear antibody test in patients with and without autoimmune disease"],"prefix":"10.1186","volume":"7","author":[{"given":"Jacy T.","family":"Zanussi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Qi","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gul","family":"Karakoc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia P.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"QiPing","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy J.","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Michael","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian K.","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,7]]},"reference":[{"key":"349_CR1","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrrheum.2017.74","volume":"13","author":"DS Pisetsky","year":"2017","unstructured":"Pisetsky DS. Antinuclear antibody testing - misunderstood or misbegotten? Nat Rev Rheumatol. 2017;13:495\u2013502.","journal-title":"Nat Rev Rheumatol"},{"key":"349_CR2","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.40930","volume":"71","author":"M Aringer","year":"2019","unstructured":"Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism\/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019;71:1400\u201312.","journal-title":"Arthritis Rheumatol"},{"key":"349_CR3","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1002\/art.34380","volume":"64","author":"M Satoh","year":"2012","unstructured":"Satoh M, Chan EK, Ho LA, et al. Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthritis Rheum. 2012;64:2319\u201327.","journal-title":"Arthritis Rheum"},{"key":"349_CR4","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jaut.2012.05.002","volume":"39","author":"FW Miller","year":"2012","unstructured":"Miller FW, Alfredsson L, Costenbader KH, et al. Epidemiology of environmental exposures and human autoimmune diseases: findings from a National Institute of Environmental Health Sciences Expert Panel Workshop. J Autoimmun. 2012;39:259\u201371.","journal-title":"J Autoimmun"},{"key":"349_CR5","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.jaci.2020.04.047","volume":"146","author":"S Slight-Webb","year":"2020","unstructured":"Slight-Webb S, Smith M, Bylinska A, et al. Autoantibody-positive healthy individuals with lower lupus risk display a unique immune endotype. J Allergy Clin Immunol. 2020;146:1419\u201333.","journal-title":"J Allergy Clin Immunol"},{"key":"349_CR6","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1002\/art.39706","volume":"68","author":"S Slight-Webb","year":"2016","unstructured":"Slight-Webb S, Lu R, Ritterhouse LL, et al. Autoantibody-positive healthy individuals display unique immune profiles that may regulate autoimmunity. Arthritis Rheumatol. 2016;68:2492\u2013502.","journal-title":"Arthritis Rheumatol"},{"key":"349_CR7","doi-asserted-by":"crossref","first-page":"R38","DOI":"10.1186\/ar3271","volume":"13","author":"QZ Li","year":"2011","unstructured":"Li QZ, Karp DR, Quan J, et al. Risk factors for ANA positivity in healthy persons. Arthritis Res Ther. 2011;13:R38.","journal-title":"Arthritis Res Ther"},{"key":"349_CR8","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1365-3083.2012.02728.x","volume":"76","author":"DS Pisetsky","year":"2012","unstructured":"Pisetsky DS. Antinuclear antibodies in rheumatic disease: a proposal for a function-based classification. Scand J Immunol. 2012;76:223\u20138.","journal-title":"Scand J Immunol"},{"key":"349_CR9","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.3899\/jrheum.090188","volume":"36","author":"KP Liang","year":"2009","unstructured":"Liang KP, Kremers HM, Crowson CS, et al. Autoantibodies and the risk of cardiovascular events. J Rheumatol. 2009;36:2462\u20139.","journal-title":"J Rheumatol"},{"key":"349_CR10","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.critrevonc.2018.05.002","volume":"127","author":"A Vlagea","year":"2018","unstructured":"Vlagea A, Falagan S, Gutierrez-Gutierrez G, et al. Antinuclear antibodies and cancer: a literature review. Crit Rev Oncol Hematol. 2018;127:42\u20139.","journal-title":"Crit Rev Oncol Hematol"},{"key":"349_CR11","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1136\/ard.2003.020198","volume":"63","author":"F Cainelli","year":"2004","unstructured":"Cainelli F, Betterle C, Vento S. Antinuclear antibodies are common in an infectious environment but do not predict systemic lupus erythematosus. Ann Rheum Dis. 2004;63:1707\u20138.","journal-title":"Ann Rheum Dis"},{"key":"349_CR12","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1016\/j.jacc.2015.03.578","volume":"65","author":"EB Solow","year":"2015","unstructured":"Solow EB, Vongpatanasin W, Skaug B, Karp DR, Ayers C, de Lemos JA. Antinuclear antibodies are associated with all-cause mortality and cardiovascular outcomes in the general population. J Am Coll Cardiol. 2015;65:2669\u201370.","journal-title":"J Am Coll Cardiol"},{"key":"349_CR13","doi-asserted-by":"crossref","first-page":"e0185977","DOI":"10.1371\/journal.pone.0185977","volume":"12","author":"GE Dinse","year":"2017","unstructured":"Dinse GE, Parks CG, Weinberg CR, et al. Antinuclear antibodies and mortality in the national health and nutrition examination survey (1999\u20132004). PLoS ONE. 2017;12:e0185977.","journal-title":"PLoS ONE"},{"key":"349_CR14","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jaut.2005.10.008","volume":"26","author":"L Rivadeneyra-Espinoza","year":"2006","unstructured":"Rivadeneyra-Espinoza L, Ruiz-Arguelles A. Cell-penetrating anti-native DNA antibodies trigger apoptosis through both the neglect and programmed pathways. J Autoimmun. 2006;26:52\u20136.","journal-title":"J Autoimmun"},{"key":"349_CR15","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1046\/j.1365-2567.2000.00970.x","volume":"99","author":"KH Sun","year":"2000","unstructured":"Sun KH, Yu CL, Tang SJ, Sun GH. Monoclonal anti-double-stranded DNA autoantibody stimulates the expression and release of IL-1beta, IL-6, IL-8, IL-10 and TNF-alpha from normal human mononuclear cells involving in the lupus pathogenesis. Immunology. 2000;99:352\u201360.","journal-title":"Immunology"},{"key":"349_CR16","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1002\/art.11161","volume":"48","author":"R Kokkola","year":"2003","unstructured":"Kokkola R, Li J, Sundberg E, et al. Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity. Arthritis Rheum. 2003;48:2052\u20138.","journal-title":"Arthritis Rheum"},{"key":"349_CR17","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13018-017-0614-z","volume":"12","author":"BF Zhang","year":"2017","unstructured":"Zhang BF, Wang PF, Cong YX, et al. Anti-high mobility group box-1 (HMGB1) antibody attenuates kidney damage following experimental crush injury and the possible role of the tumor necrosis factor-alpha and c-Jun N-terminal kinase pathway. J Orthop Surg Res. 2017;12:110.","journal-title":"J Orthop Surg Res"},{"key":"349_CR18","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.omtm.2017.05.006","volume":"6","author":"H Watanabe","year":"2017","unstructured":"Watanabe H, Watanabe KS, Liu K, et al. Anti-high mobility group box 1 antibody ameliorates albuminuria in MRL\/lpr lupus-prone mice. Mol Ther Methods Clin Dev. 2017;6:31\u20139.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"349_CR19","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1136\/annrheumdis-2018-214436","volume":"78","author":"J Damoiseaux","year":"2019","unstructured":"Damoiseaux J, Andrade LEC, Carballo OG, et al. Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective. Ann Rheum Dis. 2019;78:879\u201389.","journal-title":"Ann Rheum Dis"},{"key":"349_CR20","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/bioinformatics\/btq126","volume":"26","author":"JC Denny","year":"2010","unstructured":"Denny JC, Ritchie MD, Basford MA, et al. PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene-disease associations. Bioinformatics. 2010;26:1205\u201310.","journal-title":"Bioinformatics"},{"key":"349_CR21","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1136\/ard.2009.127100","volume":"69","author":"PL Meroni","year":"2010","unstructured":"Meroni PL, Schur PH. ANA screening: an old test with new recommendations. Ann Rheum Dis. 2010;69:1420\u20132.","journal-title":"Ann Rheum Dis"},{"key":"349_CR22","doi-asserted-by":"crossref","unstructured":"Buchner C, Bryant C, Eslami A, Lakos G. Anti-nuclear antibody screening using HEp-2 cells. J Vis Exp. 2014:e51211.","DOI":"10.3791\/51211-v"},{"key":"349_CR23","doi-asserted-by":"crossref","first-page":"e0175508","DOI":"10.1371\/journal.pone.0175508","volume":"12","author":"WQ Wei","year":"2017","unstructured":"Wei WQ, Bastarache LA, Carroll RJ, et al. Evaluating phecodes, clinical classification software, and ICD-9-CM codes for phenome-wide association studies in the electronic health record. PLoS ONE. 2017;12:e0175508.","journal-title":"PLoS ONE"},{"key":"349_CR24","doi-asserted-by":"crossref","first-page":"e14325","DOI":"10.2196\/14325","volume":"7","author":"P Wu","year":"2019","unstructured":"Wu P, Gifford A, Meng X, et al. Mapping ICD-10 and ICD-10-CM codes to phecodes: workflow development and initial evaluation. JMIR Med Inform. 2019;7:e14325.","journal-title":"JMIR Med Inform"},{"key":"349_CR25","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12859-018-2135-0","volume":"19","author":"A Verma","year":"2018","unstructured":"Verma A, Bradford Y, Dudek S, et al. A simulation study investigating power estimates in phenome-wide association studies. BMC Bioinformatics. 2018;19:120.","journal-title":"BMC Bioinformatics"},{"key":"349_CR26","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/bioinformatics\/btu197","volume":"30","author":"RJ Carroll","year":"2014","unstructured":"Carroll RJ, Bastarache L, Denny JC. R PheWAS: data analysis and plotting tools for phenome-wide association studies in the R environment. Bioinformatics. 2014;30:2375\u20136.","journal-title":"Bioinformatics"},{"key":"349_CR27","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3389\/fimmu.2018.00541","volume":"9","author":"K Didier","year":"2018","unstructured":"Didier K, Bolko L, Giusti D, et al. Autoantibodies associated with connective tissue diseases: what meaning for clinicians? Front Immunol. 2018;9:541.","journal-title":"Front Immunol"},{"key":"349_CR28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.autrev.2006.03.004","volume":"6","author":"M Mosca","year":"2006","unstructured":"Mosca M, Tani C, Neri C, Baldini C, Bombardieri S. Undifferentiated connective tissue diseases (UCTD). Autoimmun Rev. 2006;6:1\u20134.","journal-title":"Autoimmun Rev"},{"key":"349_CR29","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/art.10561","volume":"47","author":"DH Solomon","year":"2002","unstructured":"Solomon DH, Kavanaugh AJ, Schur PH, American College of Rheumatology Ad Hoc Committee on Immunologic Testing G. Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum. 2002;47:434\u201344.","journal-title":"Arthritis Rheum"},{"key":"349_CR30","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1001\/archinte.158.6.595","volume":"158","author":"G Spencer-Green","year":"1998","unstructured":"Spencer-Green G. Outcomes in primary Raynaud phenomenon: a meta-analysis of the frequency, rates, and predictors of transition to secondary diseases. Arch Intern Med. 1998;158:595\u2013600.","journal-title":"Arch Intern Med"},{"key":"349_CR31","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1164\/rccm.201010-1727ED","volume":"183","author":"CA Feghali-Bostwick","year":"2011","unstructured":"Feghali-Bostwick CA, Wilkes DS. Autoimmunity in idiopathic pulmonary fibrosis: are circulating autoantibodies pathogenic or epiphenomena? Am J Respir Crit Care Med. 2011;183:692\u20133.","journal-title":"Am J Respir Crit Care Med"},{"key":"349_CR32","first-page":"624","volume":"11","author":"R Sakthiswary","year":"2012","unstructured":"Sakthiswary R, Rajalingam S, Norazman MR, Hussein H. Antinuclear antibodies in primary osteoarthritis of the knee: a case-control study. EXCLI J. 2012;11:624\u201331.","journal-title":"EXCLI J"},{"key":"349_CR33","doi-asserted-by":"crossref","first-page":"R55","DOI":"10.1186\/ar2675","volume":"11","author":"JB Catterall","year":"2009","unstructured":"Catterall JB, Barr D, Bolognesi M, Zura RD, Kraus VB. Post-translational aging of proteins in osteoarthritic cartilage and synovial fluid as measured by isomerized aspartate. Arthritis Res Ther. 2009;11:R55.","journal-title":"Arthritis Res Ther"},{"key":"349_CR34","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.coi.2011.12.003","volume":"24","author":"HA Doyle","year":"2012","unstructured":"Doyle HA, Mamula MJ. Autoantigenesis: the evolution of protein modifications in autoimmune disease. Curr Opin Immunol. 2012;24:112\u20138.","journal-title":"Curr Opin Immunol"},{"issue":"24","key":"349_CR35","doi-asserted-by":"crossref","first-page":"15803","DOI":"10.3390\/ijms232415803","volume":"23","author":"I Haro","year":"2022","unstructured":"Haro I, Sanmarti R, Gomara MJ. Implications of post-translational modifications in autoimmunity with emphasis on citrullination, homocitrullination and acetylation for the pathogenesis, diagnosis and prognosis of rheumatoid arthritis. Int J Mol Sci. 2022;23(24):15803.","journal-title":"Int J Mol Sci"},{"key":"349_CR36","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.joca.2021.03.008","volume":"29","author":"X Xie","year":"2021","unstructured":"Xie X, van Delft MAM, Shuweihdi F, et al. Auto-antibodies to post-translationally modified proteins in osteoarthritis. Osteoarthritis Cartilage. 2021;29:924\u201333.","journal-title":"Osteoarthritis Cartilage"},{"issue":"3","key":"349_CR37","doi-asserted-by":"crossref","first-page":"e22279","DOI":"10.1002\/jcla.22279","volume":"32","author":"CM Litwin","year":"2018","unstructured":"Litwin CM, Rourk AR. Anti-ENA antibody profiles in patients with hepatitis C virus infection. J Clin Lab Anal. 2018;32(3):e22279.","journal-title":"J Clin Lab Anal"},{"key":"349_CR38","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1176\/appi.psy.48.4.286","volume":"48","author":"B Appleby","year":"2007","unstructured":"Appleby B. Are anti-nuclear antibodies common in affective disorders? A review of the past 35 years. Psychosomatics. 2007;48:286\u20139.","journal-title":"Psychosomatics"},{"key":"349_CR39","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1176\/appi.neuropsych.18040069","volume":"31","author":"SG Saether","year":"2019","unstructured":"Saether SG, Ro ADB, Larsen JB, Vaaler A, Kondziella D, Reitan SK. Biomarkers of autoimmunity in acute psychiatric disorders. J Neuropsychiatry Clin Neurosci. 2019;31:246\u201353.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"349_CR40","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jaut.2018.05.006","volume":"92","author":"GE Dinse","year":"2018","unstructured":"Dinse GE, Parks CG, Meier HCS, et al. Prescription medication use and antinuclear antibodies in the United States, 1999\u20132004. J Autoimmun. 2018;92:93\u2013103.","journal-title":"J Autoimmun"},{"key":"349_CR41","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/aps.2009.67","volume":"30","author":"WH Piao","year":"2009","unstructured":"Piao WH, Campagnolo D, Dayao C, Lukas RJ, Wu J, Shi FD. Nicotine and inflammatory neurological disorders. Acta Pharmacol Sin. 2009;30:715\u201322.","journal-title":"Acta Pharmacol Sin"},{"key":"349_CR42","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1136\/annrheumdis-2019-215463","volume":"78","author":"Y Ishikawa","year":"2019","unstructured":"Ishikawa Y, Ikari K, Hashimoto M, et al. Shared epitope defines distinct associations of cigarette smoking with levels of anticitrullinated protein antibody and rheumatoid factor. Ann Rheum Dis. 2019;78:1480\u20137.","journal-title":"Ann Rheum Dis"},{"key":"349_CR43","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s13075-016-1177-9","volume":"18","author":"TJ van Wesemael","year":"2016","unstructured":"van Wesemael TJ, Ajeganova S, Humphreys J, et al. Smoking is associated with the concurrent presence of multiple autoantibodies in rheumatoid arthritis rather than with anti-citrullinated protein antibodies per se: a multicenter cohort study. Arthritis Res Ther. 2016;18:285.","journal-title":"Arthritis Res Ther"},{"key":"349_CR44","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1002\/art.41214","volume":"72","author":"GE Dinse","year":"2020","unstructured":"Dinse GE, Parks CG, Weinberg CR, et al. Increasing prevalence of antinuclear antibodies in the United States. Arthritis Rheumatol. 2020;72:1026\u201335.","journal-title":"Arthritis Rheumatol"},{"key":"349_CR45","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/ijc.2910230504","volume":"23","author":"M Ferson","year":"1979","unstructured":"Ferson M, Edwards A, Lind A, Milton GW, Hersey P. Low natural killer-cell activity and immunoglobulin levels associated with smoking in human subjects. Int J Cancer. 1979;23:603\u20139.","journal-title":"Int J Cancer"},{"key":"349_CR46","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/bcpt.13278","volume":"125","author":"N Tarbiah","year":"2019","unstructured":"Tarbiah N, Todd I, Tighe PJ, Fairclough LC. Cigarette smoking differentially affects immunoglobulin class levels in serum and saliva: An investigation and review. Basic Clin Pharmacol Toxicol. 2019;125:474\u201383.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"349_CR47","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1164\/ajrccm\/144.3_Pt_1.612","volume":"144","author":"DJ Tollerud","year":"1991","unstructured":"Tollerud DJ, Brown LM, Blattner WA, Mann DL, Pankiw-Trost L, Hoover RN. T cell subsets in healthy black smokers and nonsmokers. Evidence for ethnic group as an important response modifier. Am Rev Respir Dis. 1991;144:612\u20136.","journal-title":"Am Rev Respir Dis"},{"key":"349_CR48","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/toxsci\/kfi217","volume":"87","author":"RL Rubin","year":"2005","unstructured":"Rubin RL, Hermanson TM, Bedrick EJ, et al. Effect of cigarette smoke on autoimmunity in murine and human systemic lupus erythematosus. Toxicol Sci. 2005;87:86\u201396.","journal-title":"Toxicol Sci"},{"key":"349_CR49","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1001\/archderm.1997.03890430023004","volume":"133","author":"CM Mills","year":"1997","unstructured":"Mills CM, Hill SA, Marks R. Transdermal nicotine suppresses cutaneous inflammation. Arch Dermatol. 1997;133:823\u20135.","journal-title":"Arch Dermatol"},{"key":"349_CR50","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJM199403243301202","volume":"330","author":"RD Pullan","year":"1994","unstructured":"Pullan RD, Rhodes J, Ganesh S, et al. Transdermal nicotine for active ulcerative colitis. N Engl J Med. 1994;330:811\u20135.","journal-title":"N Engl J Med"},{"key":"349_CR51","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2147\/ITT.S267905","volume":"10","author":"V Giorgi","year":"2021","unstructured":"Giorgi V, Marotto D, Batticciotto A, Atzeni F, Bongiovanni S, Sarzi-Puttini P. Cannabis and autoimmunity: possible mechanisms of action. Immunotargets Ther. 2021;10:261\u201371.","journal-title":"Immunotargets Ther"},{"key":"349_CR52","first-page":"5","volume":"1","author":"X Liang","year":"2016","unstructured":"Liang X, Liu R, Chen C, Ji F, Li T. Opioid system modulates the immune function: a review. Transl Perioper Pain Med. 2016;1:5\u201313.","journal-title":"Transl Perioper Pain Med"},{"key":"349_CR53","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1046\/j.1360-0443.2002.00162.x","volume":"97","author":"KP Richter","year":"2002","unstructured":"Richter KP, Ahluwalia HK, Mosier MC, Nazir N, Ahluwalia JS. A population-based study of cigarette smoking among illicit drug users in the United States. Addiction. 2002;97:861\u20139.","journal-title":"Addiction"},{"key":"349_CR54","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S1059-1311(03)00112-2","volume":"13","author":"P Debourdeau","year":"2004","unstructured":"Debourdeau P, Gerome P, Zammit C, et al. Frequency of anticardiolipin, antinuclear and anti beta2GP1 antibodies is not increased in unselected epileptic patients: a case-control study. Seizure. 2004;13:205\u20137.","journal-title":"Seizure"},{"key":"349_CR55","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.15585\/mmwr.mm6947a5","volume":"69","author":"S Sapkota","year":"2020","unstructured":"Sapkota S, Kobau R, Croft JB, King BA, Thomas C, Zack MM. Prevalence and trends in cigarette smoking among adults with epilepsy - United States, 2010\u20132017. MMWR Morb Mortal Wkly Rep. 2020;69:1792\u20136.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"349_CR56","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3389\/fimmu.2015.00221","volume":"6","author":"G Mastroianni-Kirsztajn","year":"2015","unstructured":"Mastroianni-Kirsztajn G, Hornig N, Schlumberger W. Autoantibodies in renal diseases - clinical significance and recent developments in serological detection. Front Immunol. 2015;6:221.","journal-title":"Front Immunol"},{"key":"349_CR57","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.4049\/jimmunol.1102859","volume":"188","author":"K Mannoor","year":"2012","unstructured":"Mannoor K, Matejuk A, Xu Y, Beardall M, Chen C. Expression of natural autoantibodies in MRL-lpr mice protects from lupus nephritis and improves survival. J Immunol. 2012;188:3628\u201338.","journal-title":"J Immunol"},{"key":"349_CR58","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/art.41673","volume":"73","author":"GJ Silverman","year":"2021","unstructured":"Silverman GJ. Could compensatory autoantibody production affect rheumatoid arthritis etiopathogenesis? Arthritis Rheumatol. 2021;73:728\u201330.","journal-title":"Arthritis Rheumatol"},{"key":"349_CR59","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/acr2.11271","volume":"3","author":"SS Paknikar","year":"2021","unstructured":"Paknikar SS, Crowson CS, Davis JM, Thanarajasingam U. Exploring the role of antinuclear antibody positivity in the diagnosis, treatment, and health outcomes of patients with rheumatoid arthritis. ACR Open Rheumatol. 2021;3:422\u20136.","journal-title":"ACR Open Rheumatol"},{"key":"349_CR60","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13317-020-0126-4","volume":"11","author":"GL Ortiz-Hernandez","year":"2020","unstructured":"Ortiz-Hernandez GL, Sanchez-Hernandez ES, Casiano CA. Twenty years of research on the DFS70\/LEDGF autoantibody-autoantigen system: many lessons learned but still many questions. Auto Immun Highlights. 2020;11:3.","journal-title":"Auto Immun Highlights"},{"key":"349_CR61","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/gepi.22080","volume":"41","author":"L Wang","year":"2017","unstructured":"Wang L, Damrauer SM, Zhang H, et al. Phenotype validation in electronic health records based genetic association studies. Genet Epidemiol. 2017;41:790\u2013800.","journal-title":"Genet Epidemiol"},{"key":"349_CR62","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1056\/NEJMoa021933","volume":"349","author":"MR Arbuckle","year":"2003","unstructured":"Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349:1526\u201333.","journal-title":"N Engl J Med"}],"container-title":["BMC Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-023-00349-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41927-023-00349-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-023-00349-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T23:03:16Z","timestamp":1700262196000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcrheumatol.biomedcentral.com\/articles\/10.1186\/s41927-023-00349-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,7]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["349"],"URL":"https:\/\/doi.org\/10.1186\/s41927-023-00349-4","relation":{},"ISSN":["2520-1026"],"issn-type":[{"value":"2520-1026","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,7]]},"assertion":[{"value":"6 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the Vanderbilt University Medical Center (VUMC) Institutional Review Board; the study met Exemption 4 criteria and is not considered human subject research under 2018 Revised Common Rule requirement of the Office for Human Research Protections (OHRP). Thus, consent form was not required. Data used for the study comes from de-identified electronic health record (EHR) system at VUMC. No experiments in humans were performed as part of the study, de-identified data that was already collected was used for in silico analysis, and all methods were carried out in accordance with relevant guidelines and regulations. The authors did not have direct contact or knowledge of the individuals\u2019 identity.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"24"}}